Accession Number: | 0000920465-20-000075 |
Date: | 2020-05-15 |
Issuer: | LA JOLLA PHARMACEUTICAL CO (LJPC) |
Original Submission Date: |
CHAWLA LAKHMIR S
C/O LA JOLLA PHARMACEUTICAL COMPANY,
4550 TOWNE CENTRE COURT
SAN DIEGO, CA 92121
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-05-15 | A | 335 | a | $5.86 | 9,451 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 6.89 | 2020-05-15 | deemed execution date | A | 335 (a) | 2030-05-15 | common stock 335 | $6.89 | 335 | direct |
ID | footnote |
---|---|
f1 | these shares were acquired on 05/15/2020 through the la jolla pharmaceutical company 2018 employee stock purchase plan in a transaction that was exempt under both rule 16b-3(d) and rule 16b-3(c). |
f2 | the stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. |